Overview

A Phase 2 Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer

Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This study is designed as an open-label, adaptive Simon Two-Stage study to evaluate the efficacy of CTX-009 in patients with metastatic colorectal cancer. A Simon Two-Stage adaptive design will enroll approximately 37 patients into Stage 1, and if criteria are met to move to Stage 2, an additional 47 patients will be enrolled.
Phase:
Phase 2
Details
Lead Sponsor:
Compass Therapeutics